Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Liudmila V. Fedorova"'
Autor:
Vladimir I. Vorobyev, Eduard G. Gemdzhian, Liudmila V. Fedorova, Natalia B. Mikhailova, Ridvan K. Ilyasov, Liliia P. Kaleikina, Olga S. Trubyakova, Kamil D. Kaplanov, Elena V. Melnichenko, Elena V. Martynova, Elena P. Yakovleva, Olga Yu. Li, Elena V. Tarasenko, Elena P. Chumakova, Natalia B. Bulieva, Ekaterina S. Nesterova, Oleg V. Margolin, Vera A. Zherebtsova, Lev S. Butaev, Vadim V. Ptushkin
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Background. Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activi
Externí odkaz:
https://doaj.org/article/b83a79daf0fc4b7db69564adb35219aa
Autor:
Kirill V. Lepik, Liudmila V. Fedorova, Elena V. Kondakova, Yuri R. Zalyalov, Elena V. Babenko, Elena E. Lepik, Polina V. Kotselyabina, Anastasia V. Beynarovich, Marina O. Popova, Nikita P. Volkov, Lilia V. Stelmakh, Vadim V. Baykov, Ivan S. Moiseev, Natalia B. Mikhailova, Alexander D. Kulagin, Boris V. Afanasyev
Publikováno v:
HemaSphere, Vol 4, Iss 5, p e480 (2020)
Abstract. The introduction of nivolumab has changed the landscape of relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number of patients worldw
Externí odkaz:
https://doaj.org/article/26c4ae48c6e54f8491d5fcf760d55f6c
Autor:
Kirill V. Lepik, Natalia B. Mikhailova, Elena V. Kondakova, Yuri R. Zalyalov, Liudmila V. Fedorova, Luibov A. Tsvetkova, Polina V. Kotselyabina, Evgeniya S. Borzenkova, Elena V. Babenko, Marina O. Popova, Elena I. Darskaya, Vadim V. Baykov, Ivan S. Moiseev, Boris V. Afanasyev
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e401 (2020)
Abstract. This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received
Externí odkaz:
https://doaj.org/article/4007f47d8ed2482b85babff63061e790
Publikováno v:
Modern Problems and Technologies of Innovative Development of Education; 110-114
Современные проблемы и технологии инновационного развития образования; 110-114
Современные проблемы и технологии инновационного развития образования; 110-114
В статье отмечается значимость визуального мышления младших школьников при обучении математике. Описаны средства формирования визуал
Autor:
Nikita P. Volkov, Polina V Kotselyabina, Kirill V. Lepik, Liudmila V. Fedorova, Evgenia S. Borzenkova, Andrey V. Kozlov, Vadim Baykov, Anastasia V. Beynarovich, Natalia B. Mikhailova, M. Popova, Ivan S. Moiseev, A. D. Kulagin
Publikováno v:
International Journal of Clinical Oncology
Objectives Therapy of patients with relapsed and refractory classic Hodgkin lymphoma (r/r cHL) after PD-1 inhibitors failure remains an unresolved issue. The aim of this study was to evaluate the efficacy and safety of the combination of nivolumab wi
Autor:
Liudmila V. Fedorova, Elena V. Melnichenko, Kaplanov Kd, Elena V. Martynova, Vladimir I. Vorobyev, Natalia B. Mikhailova, Liliia P. Kaleikina, Natalia B. Bulieva, Olga S. Trubyakova, Elena P. Yakovleva, Elena P. Chumakova, Elena V. Tarasenko, Vadim V. Ptushkin, Olga Yu. Li, Lev S. Butaev, Ridvan K. Ilyasov, E S Nesterova, Vera A. Zherebtsova, Margolin Ov, Eduard G. Gemdzhian
Publikováno v:
Терапевтический архив, Vol 93, Iss 7, Pp 770-777 (2021)
Mantle cell lymphoma (MCL) is a rare and clinically aggressive lymphoma subtype. Current approaches have greatly improved patients outcomes, but relapse is inevitable. In phase IIIII clinical trials, ibrutinib has shown significant activity in patien
Autor:
Kirill V. Lepik, Ivan S. Moiseev, Vadim Baykov, Andrey V. Kozlov, Liudmila V. Fedorova, Natalia B. Mikhailova, Boris V. Afanasyev, Y. Zalyalov, E. Kondakova, Elena V. Babenko
Publikováno v:
Annals of Hematology. 100:691-698
Immune checkpoint inhibitors (ICI) have demonstrated high therapeutic efficacy in relapsed or refractory classical Hodgkin lymphoma (r/r cHL). Nevertheless, despite the accumulated data, the question of the ICI therapy duration and efficacy of nivolu
Autor:
Ye.Ye. Lepik, V.V. Baikov, N. Mikhailova, Kirill V. Lepik, Liudmila V. Fedorova, L. Tsvetkova, A.V. Beinarovich, M.V. Demchenkova, Nikita P. Volkov, Polina V Kotselyabina, Boris V. Afanasyev, Ivan S. Moiseev, O.G. Smykova, Yu.R. Zalyalov, E. Kondakova
Publikováno v:
Clinical oncohematology. 13:280-288
Aim. To assess prognostic factors and to analyze the outcomes of nivolumab therapy in patients with relapsed/re-fractory classic Hodgkin's lymphoma (cHL) after autologous hematopoietic stem cell transplantation (auto-HSCT). Materials & Methods. The r
Autor:
Yury R. Zalyalov, Yulia Yu. Vlasova, Olga V. Kudyasheva, Inna V. Markova, Elena I. Darskaya, Valentina V. Porunova, Elena E. Lepik, Yulia A. Rogacheva, Anna A. Osipova, Kirill V. Lepik, Liudmila V. Fedorova, M. Popova
Publikováno v:
Cellular Therapy and Transplantation. 8:82-90
Autor:
E. Kondakova, Liudmila V. Fedorova, Natalia B. Mikhailova, Y. Zalyalov, Kirill V. Lepik, E. Borzenkova, Elena V. Babenko, Ivan S. Moiseev, M. Popova, V. Baykov, Elena I. Darskaya, Polina V Kotselyabina, L. Tsvetkova, Boris V. Afanasyev
Publikováno v:
HemaSphere, Vol 4, Iss 3, p e401 (2020)
HemaSphere
HemaSphere
This single-center prospective clinical trial evaluated the combination of nivolumab plus bendamustine (NB) as a salvage regimen in classical Hodgkin lymphoma patients after failure of nivolumab monotherapy. A total of 30 patients received nivolumab